Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAPION: Randomized, placebo-controlled, double-blind study of 2LPAPI for clearance of genital high-risk HPV infections
2024-513969-39-00Phase 4Authorised
- Sponsor
- Labo'Life
- Start
- May 2024
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial in human papillomavirus infection comparing 2LPAPI with Placebo (2 arms). Primary endpoint: HR-HPV infection clearance at 12 months. Planned start May 2024; status: authorised.
02
Drugs
2LPAPI
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on 2024-513969-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513969-39-00.